Full Press Release Details
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia – Zai Lab Limited.
ZLAB
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia – Zai Lab Limited
Key Takeaway: argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia – Zai Lab Limited
Price reaction · baseline $16.25 (2024-03-25 close) · hit after-hours · 2 other ZLAB headline(s) in the window, move may be shared
day 0 close · peak
-1.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Cash runway
~28 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Small-cell Lung Cancer